November 20, 2023

Capivasertib for Breast Cancer, Repotrectinib for NSCLC, Enzalutamide for Prostate Cancer, Pembrolizumab for Stomach Cancer, Hypertension Device

10 minutes

Check out our free downloads at nascentmc.com:

Implementing AMA Style – 8 Things to Get Right in Your Next Project
Needs Assessments – 7 Essentials for Getting Funded
Working With Your Medical Writer – 8 Ways to Get the Most out of Them

See the full write ups for today's episode at nascentmc.com/podcast

Here are the highlights:

· Capivasertib (Truqap) has been FDA-approved for the treatment of hormone receptor-positive/HER2-negative breast cancer with AKT pathway alterations, showing improved progression-free survival in clinical trials.

· Repotrectinib (Augtyro) has received FDA approval for ROS1-positive non-small cell lung cancer (NSCLC), demonstrating high response rates in patients who had not received a prior tyrosine kinase inhibitor.

· Enzalutamide (Xtandi) has gained FDA approval for nonmetastatic castration-sensitive prostate cancer (nmCSPC) in high-risk patients with biochemical recurrence, expanding its use in prostate cancer treatment.

· Pembrolizumab (Keytruda) has received supplemental approval for the first-line treatment of HER2-negative stomach cancer when combined with chemotherapy, showing improved overall survival compared to chemotherapy alone.

· The Symplicity Spyral™ renal denervation (RDN) system has been approved by the FDA for treating hypertension through a minimally invasive procedure targeting overactive nerves near the kidneys.

· A combination of taurolidine and heparin catheter lock solution (DefenCath) has been approved for preventing catheter-related bloodstream infections in hemodialysis patients, demonstrating a significant reduction in infection risk in clinical trials.

Intro and outro music

Garden Of Love by Pk jazz Collective

...more

View all episodes

By Emma Hitt Nichols, PhD

44 ratings